Paclitaxel

As with any market strategy, there are both advantages and disadvantages to retooling one's business. We can derive what the advantages and disadvantages will be from two viewpoints: that of the supplier e.g., drug companies ; and that of the consumer e.g, patients ; . I believe that most of the economic advantages will be conferred on drug companies while consumers will experience a merely marginal economic advantage compared to the overall societal economic disadvantages they will have to bear.59 The economic advantages of introducing pharmacogenomic techniques into the marketplace will putatively benefit drug companies in the following ways: 1 ; reduction in the costs associated with drug development and clinical trials, and 2 ; further refinement of their ability to identify target markets. As Allen Roses, head of GlaxoSmithKline's Genetics division, observes: [T]here are . enormous economical costs associated with searching huge lists of genes for `the right disease for the available gene.' It is correct to state that target validation is a major challenge to the pharmaceutical industry, but it is also critical to realize that the core problem for drug development is poor target selection Each failure is very expensive in lost time and money.60 According to the Boston Consulting Group, drug companies are estimated to save "an average of 0 million and two years per new drug as a result of increased efficiency, "61 a significant figure.
DMD#2238RR TABLE 2 Correlation of laquinimod metabolites M1-M6 ; formation with total CYP content and with different CYP activities across a panel of human liver microsomes n 15 ; Correlation r2 ; Marker activity Total CYP content 7-Ethoxyresorufin O-dealkylation Coumarin 7-hydroxylation 7-Ehoxy-4-trifluoromethylcoumarin O-deethylation Paclitaxel 6-hydroxylation Tolbutamide methyl-hydroxylation S-Mephenytoin 4-hydroxylation Dextromethorphan O-demethylation Chlorzoxazone 6-hydroxylation 2E1 0.02. Fig. 3 Antitumor effect of PG-TXL on murine HCa-1 hepatocarcinoma tumor implanted i.m. in C3Hf Kam mice. The drugs were injected i.v. in a single dose when tumor volume measured 400 600 mm3. Data are presented as mean SD of tumor volumes. A, results in mice who received injections of Cremophor vehicle, free paclitaxel in Cremophor vehicle, or a combination of PG and paclitaxel. B, results in mice who received injections of saline, PG, or PG-TXL. C, percentage weight change versus time. Treatment groups are indicated in the inset. PGTXL was dissolved in saline 10 mg of equivalent paclitaxel ml ; , and paclitaxel was dissolved in Cremophor EL vehicle 6 mg ml. Home about us accessmylibrary browse a angiogenesis weekly mar-02 docetaxel strength greater than paclitaxel for antiangiogenesis. There' still time to apply for funding to Regional Arts Victoria' new Regional Cultural Partnerships s s program. The deadline has been extended by two weeks to Monday 21 March 2005. This program will offer five regionally based Victorian arts cultural organisations , 000 per annum over three years and will essentially support a full time regional arts development officer position. Applicants will need to demonstrate that they have matching funding ie , 000 per year over three years ; from local government or another major local organisation. Applicants to this program must contact RAV staff on 03 9644 1800 in the first instance to discuss their application. The Regional Arts Fund RAF ; is an initiative of the Commonwealth Government, supporting the arts in regional, rural and remote Australia. The Commonwealth Government has determined the objectives and general eligibility of the fund. Regional Arts Victoria will administer the RAF in Victoria until 30 June 2005. The Regional Arts Fund is designed to support arts and cultural projects that offer long-term impact, sustainability and skills development opportunities. It has been created to support arts projects that demonstrate partnerships between professional artists, arts & cultural groups, businesses, local government and the wider community. Projects must demonstrate how they contribute to the development of the arts as well as appropriate consultation with project partners in the development process. Here are the categories. The maximum-tolerated dose MTD ; of once-daily radiotherapy has been found to be at least 70 Gy [36]. CALGB 39808 explored this further in the phase II setting [37]; 57 patients were treated with 70 Gy in fractions concurrent with carboplatin plus etoposide after two induction cycles of paclitaxel and topotecan. The 2-year overall survival rate was 48%, while 16% 5% ; of patients reported grade 3 4 ; dysphagia. The CALGB has completed further studies CALGB 30002 and 30202 ; of 70 Gy thoracic radiotherapy with different chemotherapy combinations in 140 additional patients. Still, the experience with 70 Gy of radiotherapy to the chest in SCLC is limited. A recent Patterns of Care study showed that the median radiotherapy dose used in the community was 50.4 Gy [38]. The current National Comprehensive Cancer Network guidelines suggest a dose of at least 50 Gy be administered; we do recognize that stronger evidence supporting a doseresponse relationship in SCLC is needed and palonosetron. RECOMMENDATION 6-6: The MOSAIC Members therefore recommend that the MOSAIC Regional ATM Concept should: mainly focus on the overall reduction of fuel burn by looking at improving the actual ATM procedures in particular concentrate on optimizing 4D-trajectories, including advanced flow capacity management, towards the most direct routes at the most economical level minimizing ground holding times, using advanced Airport Collaborative Decision Making A-CDM ; The MOSAIC Regional ATM Concept supports engine-off ground holding times over any wasted engine-on time at those airports where capacity limitation does not allow unrestricted travel. Supporting this principle is not only an environmental issue, but it contributes also to the overall safety at major aerodromes. Carboplatin Paclitaxel or Carboplatin Vinorelbine Followed by Accelerated Hyperfractionated Conformal Radiation Therapy: A Preliminary Report of a Phase I Dose Escalation Trial from the Carolina Conformal Therapy Consortium M. A. Socinski, L.B. Marks, J. Garst, G.S. Sibley, W. Blackstock, A. Turrisi, J. Herndon, S. Zhou, M. Anscher, J. Crawford, T. Shafman and J. Rosenman Oncologist 2001; 6; 20-24 DOI: 10.1634 theoncologist.6-suppl 1-20 and pamidronate.

What is Paclitaxel Peripheral neuropathy is a common side effect of a wide variety of cancer chemotherapeutic agents. The mechanisms of this neuropathy are usually attributed to microtubule disruption taxanes, Vinca alkaloids ; or a direct toxic effect platinum compounds ; . Dose-limiting peripheral neuropathy is most often observed in the setting of advanced cancer necessitating a change in therapy while the patient is still actively responding to the agent. Even when alternative schedules are used shorter versus longer infusion ; peripheral neuropathy grade 2, as evidenced by moderate motor and sensory symptoms, is noted in up to 30% of patients receiving paclitaxel 1, 2 ; . The options of stopping treatment early or dose reducing are equally undesirable in the advanced disease setting but may have greater implications in the adjuvant setting because taxanes may become part of the standard treatment of node-positive breast cancer. In the adjuvant setting, the potential for affecting larger numbers of patients increases, because it is estimated that at least 56, 000 patients will be considered for adjuvant taxane use for node-positive disease 30% of all breast cancers ; . If the node-negative trials reveal an advantage with adjuvant taxanes, then, potentially, the number of patients affected by peripheral neuropathy will widen considerably. Paclitaxel has a broad spectrum of activity against a wide variety of neoplasms, including breast, ovary, lung, and gastrointestinal tumors. It is generally well tolerated with dose-limiting neutropenia and peripheral neuropathy after multiple cycles. The neuropathy, generally a sensory polyneuropathy affecting large fibers, can also lead to cranial nerve palsies, motor weakness, and autonomic dysfunction 3, 4 ; . Several avenues have been explored to ameliorate the neurotoxicity associated with paclitaxel, including the use of nonsteroidal anti-inflammatory agents, corticosteroids, and amifostine; and these treatments have been uniformly unsuccessful 5, 6 ; . Recently, Savarese et al. 7 ; reported the successful reduction of paclitaxel-associated myalgias and arthralgias by glutamine in five patients treated with paclitaxel doses ranging from 175 to 200 mg m2. All of the patients had debilitating paclitaxel-associated myalgias arthralgias associated with their. Three patients 6% ; were not referred for surgery. These patients had large tumours located above the carina and enlarged mediastinal lymph nodes that remained unchanged during chemotherapy, and were considered not fit enough for thoracotomy due to co and papaverine. Study subject characteristics are given in Table 1. As described previously, each girl provided institutionally approved written informed assent and parental consent before participation 4 ; . PCOS was defined by clinical acne and Ferriman-Gallwey hirsutism score, 9 ; and biochemical hyperandrogenism an elevated morning serum concentration of testosterone or androstenedione ; with peripubertal onset of oligo- or amenorrhea in a euthyroid, euprolactinemic, and otherwise healthy individual. Adolescents with PCOS n 12; mean sem chronological age, 16.4 0.57 yr ; and eumenorrheic late pubertal girls of comparable age n 10; age, 16.5 0.45 yr ; were studied contemporaneously throughout the year. Postmenarchal ages years ; were similar at 4.8 0.39 PCOS ; and 4.0 0.36 control; P NS ; . Girls with PCOS who were anovulatory n 4 ; were sampled at a random time. The other eight patients with PCOS and all controls were studied in the early follicular TABLE 1. Clinical characteristics of adolescents with PCOS and postmenarchal age-matched eumenorrheic controls.

Paclitaxel ingredients Levine DA, see Spentzos D Levine M, see Lukka H see Parulekar WR see Sathya JR see Simunovic M see Whelan T Levine M, Kakkar AK. Catheter-Associated Thrombosis: Thromboprophylaxis or Not? editorial ; , 4006 Levine MN, see Lee AYY Levine MN. In Reply correspondence ; , 7244 Levine MN, Lee AYY, Kakkar AK. In Reply correspondence ; , 7250 Levine MN, Mamounas EP, Ganz PA, Piccart-Gebhart MJ. Preface to Special Edition on Breast Cancer, 1595 Levine MN, Pritchard KI, Bramwell VHC, Shepherd LE, Tu D, Paul N. Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5, 5166 Levine MN. Trastuzumab Cardiac Side Effects: Only Time Will Tell editorial ; , 7775 Levine P, see Robbins KT Levine RL, see Frohling S Levis A, see Gobbi PG Levitt R, see Alberts SR see Witzig TE LeVoyer T, see Berger AC Levy C, see Attia P Levy DE, see Rothenberg ML Levy E, see Scotte F Levy M, Copie-Bergman C, Gameiro C, Chaumette M-T, Delfau-Larue M-H, Haioun C, Charachon A, Hemery F, Gaulard P, Leroy K, Delchier J-C. Prognostic Value of Translocation t 11; 18 ; in Tumoral Response of Low-Grade Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue Type to Oral Chemotherapy, 5061 Levy V, see Thiery G Lew D, see Hutchins LF Lew DL, see Pierce LJ Lewis I, see Nathan SS Lewis K, see Koyanagi K Lewis S, see Menon U Lewisd MT, see Chang JC Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makh son A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E. Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study, 5960 Leys RB, see Bontenbal M Li FP, see Emmons KM see Kleinerman RA see Park ER Li FP, Fletcher JA, Heinrich MC, Garber JE, Sallan SE, CurielLewandrowski C, Duensing A, van de Rijn M, Schnipper LE, Demetri GD. Familial Gastrointestinal Stromal Tumor Syndrome: Phenotypic and Molecular Features in a Kindred, 2735 Li G, see Dai DL Li J, Juliar B, Yiannoutsos C, Ansari R, Fox E, Fisch MJ, Einhorn LH, Sweeney CJ. Weekly Paclitaxel and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium: A Phase II Hoosier Oncology Group Study, 1185 Li S, see Chen S see Grundy PE see Tomlinson GE and parnate. The NICE guidelines suggest that someone with urinary continence problems should start with immediate-release oxybutynin unless there is reason to believe that he or she will experience side effects. Oxybutynin hydrochloride: twice or three times daily Trospium chloride: twice or three times daily Propiverine hydrochloride: twice three times daily. Postoperative generalized shaking is usually because of shivering, which may be thermoregulatory or non-thermoregulatory.6 The latter is thought to be secondary to the effects of volatile anaesthetics, pain or both.7 The movements generated by shivering can be severe and may even mimic a generalized seizure. Shivering is common after surgery with a stated incidence of 570%, 8 and is usually easy to diagnose. Postoperative seizures except after neurosurgery ; , however, are rare events and thus tend to be cited only in case reports.914 When they do occur, they are usually attributable to an identiable drug reaction, or a metabolic or neurological event.15 Certain anaesthetic drugs cause dystonic movements or epileptiform activity, but anaesthetic drug-induced convulsions are rare.15 The incidence of post-neurosurgical seizures is higher and ranges from 4% after aneurysm surgery to 13.5% after brain tumour surgery.16 Another cause of generalized shaking, psychogenic seizures, appears to be not uncommon in the postoperative period.17 These are attacks resembling grand mal ts but are not associated with abnormal electrical discharges in the brain. Pseudoseizures in general tend to follow a certain pattern; 17 there may be a history of convulsions and or status, and a background of psychosomatic illness. Convulsive episodes tend to be amboyant, to last longer than 90 s with asynchronous limb movement, side-to-side head movement, closed eyes with resistance to eye opening, and retained pupillary responses. Release of the arm over the head is often purposely modied during psychogenic attacks. There is usually no cyanosis, but there may be incontinence and tongue biting. Consciousness may be uctuating or blunted. The episodes may settle with reassurance. There is an absence of the usual post-ictal period. The episodes tend to become more violent with time, to occur in the presence of doctors, and to be aggravated by the use of anticonvulsants. It is possible for both epileptic and psychogenic seizures to coexist.1 One study of mixed seizure disorders suggested that 10% of patients had both.2 Clinical observation has long been used to differentiate epileptic seizures from pseudoepileptic seizures.3 This is not always reliable, 4 18 however, and in recent years diagnosis has been aided by the use of video-EEG monitoring, serum prolactin levels, and neuropsychological assessments. Unfortunately, these investigations also have limitations, 3 and most cases of pseudoseizures managed by our tertiary referral neurological centre are still based on a clinical diagnosis alone. This is because of the difcult logistics of and paromomycin. Cost of Paclitaxel

By Andrew Pollack Genentech Inc.'s cancer drug Avastin prolonged the lives of patients with advanced lung cancer in a clinical trial, a result that sent the company's shares soaring and could pave the way for wider use of what is widely considered the company's most promising product. In the trial, sponsored by the National Cancer Institute, patients who received Avastin along with standard chemotherapy drugs had a median survival of 12.5 months, compared with 10.2 months for those receiving only the chemotherapy. In the trial, 878 patients received either the chemotherapy drugs paclitaxel and carboplatin, or those drugs plus Avastin. The biggest side effect was fatal or life-threatening bleeding from the lungs. The National Cancer Institute said this occurred "infrequently." Dr. Scott Saxman of the institute said that meant it happened in fewer than 3% of the patients. But the deaths and bleeding cases occurred despite efforts to minimize them by excluding certain types of patients who, in an earlier trial, had seemed most prone to the side effect. The exclusions, of people with a type of cancer called squamous cell carcinoma and of patients whose cancer had spread to the brain, would amount to roughly one third of patients with advanced non-small cell lung cancer, specialists estimated. Animals were anesthetized for the duration of the experiment. After emptying urine from the bladder, an intravesical dose of paclitaxel-loaded gelatin nanoparticles, containing 1, 000 g of paclitaxel dispersed in 20 mL physiologic saline, was instilled into the bladder. One dog was given only the vehicle blank nanoparticles ; , and its bladder was used to prepare the standard curve samples. Animals were euthanized with an overdose of intravenous pentobarbital immediately after removal of the bladder. Serial urine samples were collected before and during instillation and immediately before surgical removal of the bladder. To analyze the total paclitaxel concentration, urine samples were incubated with 1 mg mL Pronase 1: ; at 37C for 1 hour, and 50 L of the internal standard cephalomannine, 20 g mL ; were then added. The mixture was extracted with 6 mL of ethyl acetate and centrifuged at 3, 000 rpm for 10 minutes. The supernatant was transferred and evaporated to dryness under a stream of air. The residue was reconstituted and injected into the HPLC system. The excised bladder was cut into three sections i.e., left and right lateral sides and dome ; . The tissue sections were snap-frozen in liquid nitrogen on a flat stainless steel plate cooled on dry ice. The procedures between removing the urine and freezing the bladder tissue were completed as rapidly as possible i.e., in 5 minutes ; . The rapid removal and freezing were necessary to maintain the concentration gradient between urine and tissue and to avoid washout of the drug during tissue processing. The paclitaxel concentrations in bladder tissues were determined. Frozen bladder wall tissues were cut in parallel to the urothelial surface into 10- or 20- m slices using a cryotome, as described previously 22 ; . The first two sections were discarded to avoid contamination of tissue by urine, which contained a high drug concentration. The subsequent sections, representing a tissue depth of 40 to 300 m, were used to analyze the total paclitaxel concentrations. Briefly, tissues were weighed, spiked with 50 L of the internal standard cephalomannine, 20 g mL ; , and homogenized with 3 mL of ethyl acetate. The homogenizer probe was washed with a second portion of ethyl acetate to recover residual adhering tissue. The two ethyl acetate fractions were combined and centrifuged at 3, 000 rpm for 10 minutes. The supernatant was transferred and evaporated to dryness under a stream of air. The residue was reconstituted and injected into the HPLC system. High-Pressure Liquid Chromatography Analysis of Paclitaxel. Paclitaxel was analyzed using our previously reported column-switching HPLC method 28 ; . Briefly, the HPLC stationary phase consisted of a clean-up column Novapak C8; 75 3.9-mm inner diameter; 4- m particle size; Waters Associated, Milford, MA ; and an analytical column Bakerbond C18; 250 4.6-mm inner diameter; 5- m particle size; I.D. Baker, Phillipsburg, NJ ; . The clean-up mobile phase was 37.5% acetonitrile in water at a flow rate of 1 mL min, and the analytical mobile phase was 49% acetonitrile at a flow rate of 1.2 mL min. The fraction from 8 to 15 minutes containing paclitaxel and cephalomannine was transferred from the clean-up column into the analytical column. The limit of sensitivity for paclitaxel was 5 ng mL for urine samples and 5 ng per injection for tissue samples and pbz.

FIG. 1. Standard curve constructed in assay media with 17 -estradiol standards. Interpolation of unknown represented. Unknown depicted here could represent any of the herbs studied, because all were extracted to fall in this portion of the standard curve. TABLE 1. Estradiol-like activity in herbs.
7. In the IES trial, switching to an aromatase inhibitor after tamoxifen therapy is associated with a reduced risk of breast cancer recurrence. a. True b. False and pediatric. DJ-927 DJ-927 is a new oral taxane analog designed to overcome drug resistance and improve clinical efficacy. Preclinically, this compound has shown marked efficacy in vitro and in vivo in various tumor cell lines. DJ-927 displayed higher intracellular concentrations in P-glycoprotein-expressing tumors and enhanced potency compared with both paclitaxel and docetaxel [86]. In mice, dogs and monkeys, the pharmacokinetic profile of DJ-927 was compared with standard taxanes [87]. The authors reported that DJ-927 has many similar pharmacokinetic characteristics compared with commercially available taxanes, including route of elimination, degree of plasma protein binding and wide distribution to all tissue except the brain. In contrast, DJ-927 is well absorbed and displays a long biologic half-life when administered orally. Its oral bioavailability eliminates the need for toxic vehicles and attendant hypersensitivity reactions. A phase I study to determine its MTD and characterize its toxicity profile is ongoing [88]. In this study, patients with advanced malignancies receive DJ-927 as a single oral 3-weekly dose at doses ranging from 1.5 to 40 mg m2. Above the MTD of 27 mg m2, neutropenia was dose-related and dose-limiting. Minor reponses were observed in one patient with breast cancer and another with bladder carcinoma; disease stabilization was seen in 15 35% ; patients. Pharmacokinetic analysis indicates dose-proportional absorption and long elimination half-life 180 h ; . BMS-275183 BMS-275183, a analog, is yet another orally bioavailable 24% in humans ; and efficacious novel taxane currently in phase I clinical trials [89, 90]. In vitro, BMS-275183 demonstrated similar potency to paclitaxel. Interestingly, in an MDR-overexpressing tumor cell line, a rather modest loss of potency was seen compared with. This study addressed the safety, pharmacology, and efficacy of the combination of the PKC- inhibitor LY900003 with cisplatin and gemcitabine in a sequential phase I II study in NSCLC patients. The rationale for the development of this study included the known role of PKC isoforms in malignant transformation and proliferation 1114 ; , as well as in the regulation of the phosphatidylinositol 3 -kinase Akt and MEK extracellular signal-regulated kinase pathways 20, 33 ; . These pathways have been found to be constitutively active in the majority of NSCLC cell lines and can promote cellular survival and resistance to chemotherapy 33 ; . The combination with cisplatin and gemcitabine was therefore expected to augment the antitumor activity of this chemotherapy regimen in NSCLC patients. Results of the phase I portion of this study showed an acceptable safety profile for the combination. With the exception of cathether-related complications, the toxicity was very similar to what is generally expected for the cisplatin gemcitabine regimen. In addition, the results of the pharmacokinetic studies indicate that no interactions between the agents occur. Clinical benefit was observed in patients with mesothelioma, NSCLC, and pancreatic adenocarcinoma. The phase II portion accrued a total of 55 patients, 11 of whom were treated at slightly higher doses of gemcitabine. The number of patients treated should be considered adequate to judge whether a regimen's activity in NSCLC is promising enough for further evaluation in the randomized setting. The response rate was 33% 16 of 48 evaluable patients the time to tumor progression was 4.3 months, and the overall survival for the entire group of 55 patients was 8.9 months. Although the observed response rate for the LY900003 cisplatin gemcitabine combination is slightly better than the activity reported for the cisplatin and gemcitabine combination in some but not all large multicenter studies 4, 7 ; , this activity was lower than the prospectively set response rate of interest. Our results, together with the lack of benefit of LY900003 in combination with paclitaxel carboplatin in a recently reported randomized phase III trial 34 ; , raise important questions regarding the role of this treatment in unselected NSCLC patients. At this juncture, further development of LY900003 in NSCLC depends on the answer to a number of questions. How relevant a target is PKC- in NSCLC? Furthermore, was the failure to demonstrate clinical benefit in these trials related to either a less than optimal target inhibition at the dose tested, the "unselected" nature of the patients in terms of PKC- expression, or the use of a suboptimal sequence of administration i.e., concurrent versus sequential administration ; ? Available data suggest that the doses recommended for and pegasys.

Severe symptoms usually occur within the first 10 minutes of paclitaxel infusion , after the first or second dose of paclitaxel.
J urol 2003; 169: 943-945 hussain m, petrylak d, dunn r, vaishampayan u, lara pn, chatta g, et al trastuzumab t ; , paclitaxel p ; , carboplatin c ; , and gemcitabine g ; in advanced her2-positive urothelial carcinoma: results of a multi-center phase ii nci trial and pegfilgrastim and paclitaxel. 1039 based chemotherapy have a poor outlook, whatever drug References used. Moreover, we found that response to high-dose epirubicin in patients with persistent disease, i.e., pa1. McGuire WP. Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998; 25: 340-8. tients with stable disease disease during after first-line 2. McGuire WP, Hoskins WJ. Brady MF et al. Cyclophosphamide therapy or those with partial response in first-line but and cisplatin compared with paclitaxel and cisplatin in patients still having clinically detectable residual disease was with stage III and IV ovarian cancer. N Engl J Med 1996; 334limited as well 12% ; . Only patients with late relapses 1-6. showed better results. 3. Stuart G. Bertelsen K. Mangioni C et al. Updated analysis shows a highly significant improved overall survival for cisplatin--pacliThe present study is in agreement with our previous taxel as first-line treatment of advanced ovarian cancer: Mature phase I experience [16] and again suggests that the dose results of the EORTC-GCCG. NOCOVA, NCIC CTG and of epirubicin used may be of importance. In three trials Scottish IntergroupTrial. Proc Soc Clin Oncol 1998; 17: 361. using an epirubicin dose of 50-110 mg m2 in a total of 4. Canetta RM. The development of new cytotoxic drugs for ovarian 62 platinum pretreated patients only 6 responses were cancer: Review of the literature and methodological aspects. Forum 1994; 4: 47-65. seen i.e., a response rate of 9.7% ; [21-23]. The recent 5. The Ovarian Cancer Meta-Analysis Project. Cyclophosphamide report of the Danish group [24] showing a 26% response plus cisplatin vs. cyclophosphamide, doxorubicin, and cisplatin rate with the use of 90 mg m2 is not in line with this. chemotherapy of ovarian carcinoma: A meta-analysis. J Clin Most likely, these varying response data can be explained Oncol 1991: 9: 1668-74. by differences in tumor burden and histology, various 6. Fanning J, Benner TZ, Hilgers RD. Meta-analysis of cisplatin, definitions of resistance to prior platinum treatment, or doxorubicin, and cyclophosphamide vs. cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol other presently unknown biologic factors as recently 1992; 80: 954-60. suggested from a multivariate analysis of 704 platinum 7. A'Hern RP, Gore ME. Impact of doxorubicin on survival in pre-treated patients [19]. Unfortunately, for that reason advanced ovarian cancer. J Clin Oncol 1995; 13: 726-32. it leaves the dose-response question for anthracyclines in 8. West RJ, Zweig SF. Meta-analysis of chemotherapy regimens ovarian cancer patients, at least in the recurrent disease for ovarian carcinoma: A reassessment of cisplatin, cyclophosphamide and doxorubicin vs. cisplatin and cyclophosphamide. setting, still unanswered, however, suggestive the in vitro Eur J Gynaecol Oncol 1997; 18: 343-8. data may be [25-27]. Nevertheless, with the consistency 9. Stanhope CR, Smith JP, Rudlege F. Second trial drugs in ovarian in our findings we consider the issue of dose important cancer. Gynecol Oncol 1977; 5: 52-8 when using anthracyclines in first line. 10 Hubbard SM, Barkes P, Young RC. Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy. Cancer The use of an anthracycline in first-line is becoming Treat Rep 1978; 62: 1375-7. more and more attractive, not only because of the earlier 11. Bolis G, D'lncalci M, Gramellini F, Mangioni C. Adriamycin in mentioned meta-analyses data, but also because of ovarian cancer patients resistant to cyclophosphamide. Eur J the promising clinical activity of the combined use of Cancer 1978; 14: 1401-2. paclitaxel and anthracyclines in breast cancer [28]. As 12. Ozols RF, Cunnion RE, Klecker RW et al Verapamil and adriaepirubicin has a more attractive toxicity profile than mycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987, 5: 641-7. doxorubicin, it is the preferable drug infirst-linecombinations. Various pilot studies have shown the feasibility 13. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor of platinum-taxoid-anthracycline combinations in activity and toxicity modificstions by liposomal encapsulation. ovarian cancer patients, including those of epirubicin J Clin Oncol 1997; 15: 987-93. with carboplatin and a taxoid [29]. To pursue this, at 14. Vermorken JB, Kobierska A, Chevallier B et al. Phase II study of high-dose epirubicin HDE ; in ovarian cancer patients previously least two international trials are underway evaluating treated with cisplatin. Proc Soc Clin Oncol 1995, 14: 275. the comparison of first-line carboplatin-paclitaxel vs. 15. Vermorken JB, Ten Bokkel Huinink WW, Kobierska A et al. carboplatin-paclitaxel plus epirubicin [29]. Mind a 54 K 1995 Utilities Screen Stuff MIND is a program whose primary function is to display reminders on the computer screen. These reminders are associated with reasonably flexible time intervals during which they are valid. In addition, MIND also supports the automatic execution of other programs at specified times. Snap 2.1 a 76 K 1999 Utilities Screen Stuff Snap 2.1 is a shareware application that allows you to take a snapshot of a rectangular portion of the MacintoshTM screen and save it in a window for later use. Once created, the snapshot can be inverted, moved, saved as a PICT file, copied to the Clipboard and pasted into applications such as HyperCard, MacDraw, or WriteNow ; , printed, or just left hanging around on-screen for reference. Snap 2.1 handles color, snapshots on or across multiple monitors, and multiple snapshots. Alias Zoo 2.0.8 a 242 K Appears to verify and correct aliases. 5 2 1996 Utilities Search and pegvisomant. IVAX CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-- Continued ; In thousands, except per share data ; into agreements with indirect customers, which establish contract pricing for certain products, which the wholesalers provide. Under either arrangement, we will provide credit to the wholesaler for any difference between the contracted price with the indirect party and the wholesaler's invoice price. Such credit is called a chargeback. The provision for chargebacks is based on our historical chargeback experience and estimated wholesaler inventory levels, as well as expected sell-through levels by our wholesale customers to indirect customers. Our estimates of inventory at wholesale customers and in the distribution channels are subject to inherent limitations of estimates that rely on third-party data, as certain third-party information may itself rely on estimates, and reflect other limitations. We continually monitor our provision for chargebacks and make adjustments when we believe that actual chargebacks may differ from established reserves. Returns--Consistent with industry practice, we maintain a return policy in certain markets that allows our customers to return product within a specified period prior to, and subsequent to, the product's expiration date. Our estimate of the provision for returns is based upon our historical experience with actual returns and estimated levels of inventory in the distribution channel. We make adjustments to the provision for returns in the event that it appears that actual product returns may differ from our established reserves. Shelf Stock Adjustments--Shelf stock adjustments are credits issued to reflect decreases in the selling prices of our products and are based upon our estimates of the amount of product that our customers have remaining in their inventories at the time of the anticipated price reduction. Decreases in our selling prices are discretionary decisions we make to reflect market conditions. We have contractual agreements with many of our customers which require that we grant these customers inventory credit following a price decrease. In other cases, the determination to grant a credit to a customer following a price decrease is at our discretion. These credits allow customers with established inventories to compete with those buying product at the current market price, and allow us to maintain shelf space, market share and customer loyalty. Amounts recorded for estimated shelf stock adjustments are based upon specified terms with certain customers, estimated launch dates of competing products, estimated declines in market price and estimates of inventory held by the customer. These estimates are subject to inherent limitations of estimates that rely on third-party data, as certain third-party information may itself rely on estimates, and reflect other limitations. We regularly monitor these and other factors and evaluate our reserves and estimates as additional information becomes available. In accordance with EITF Issue No. 00-21, Revenue Arrangements with Multiple Deliverables, our accounting policy is to review each contract to determine if there are multiple revenue-generating activities that constitute more than one unit of accounting. Revenue is recognized for each unit of accounting based on revenue recognition criteria relevant to that unit. Up-front payments are deferred, if appropriate, and recognized into revenues over the obligation period. During the first quarter of 2004, we earned a , 500 milestone payment under a product collaboration and development agreement with Mayne Group Limited for the marketing and distribution of our injectable paclitaxel product in Europe. This agreement is a multiple-element revenue arrangement containing a development and regulatory approval component. When the obligations and criteria for earning the milestone were satisfied, the milestone was recognized in other revenue. The arrangement also includes a license component containing a profit-split arrangement and an up-front payment that we received and deferred that is being amortized to other revenue over the license term due to obligations under the license agreement. In addition, the agreement contained a short-term supply arrangement that we determined contained fair market terms. During the second quarter of 2005, we renegotiated our arrangement with Mayne to provide Mayne with an exclusive license in perpetuity of the marketing rights for Paxene in the same countries and received , 000 during the second quarter of 2005, which, after deduction of a related intangible asset, resulted in a net gain of , 100. That gain was deferred as of the June 10, 2005, signing date due to certain obligations we had through December 31, 2005. As of June 30, 2005, deferred revenue under the Mayne arrangement totaled I-16.

Values are mean SEM. * P 0.001 vs healthy subjects. Approximately one-third of oncologists have observed allergic reactions to either docetaxel or paclitaxel, but this only occurs in a small fraction of patients. The spectrum of allergic symptoms observed in patients receiving paclitaxel is very similar to those observed in patients receiving docetaxel.
In regard to their proportion of poor or good responders as shown in Table 4. The majority 61% ; of the stromal predominant WT showed little change in their size during preoperative therapy. As 13 out of 36 even increased up to 10% of the initial volume and 9 out of 36 that showed only a marginal decrease of less than 10% of their initial volume. In the remaining cases no volume reduction of more than 50% was observed. Moreover, half of the tumors showed minimal regression on histologic analysis less than 25% regression ; . The other half showed 25%--35% regressive changes of the tumor mass. The clinical response of the epithelial predominant WTwas similar as there was only one with very good reduction, but six of eight patients had only a poor response. In contrast, more than half of the tumors in each of the other WT mixed, blastemal predominant, regressive-change predominant and completely necrotic ; were good responders. Still, 4 tumors with predominant regressive changes even doubled their initial size due to big cystic structures progressing further during pretreatment and even 2 of 17 completely necrotic tumors enlarged markedly during pretreatment. Follow-up information range 48-126 months ; was available in all but two patients who were lost to followup in their first complete remission CR ; at 2.1 and 2.9 years after the diagnosis, respectively. Additionally, five other patients died of other reasons than the primary or recurrent WT including three who died of treatment toxicity during the first, second and fourth month of treatment, one who died of a metachronous disease on the contralateral side that developed 3.3 years after the primary diagnosis, and one who died of a non-tumor related illness while in CR for more than 3.5 years. The vast majority of the patients, whose course was properly followed for at least four years 298 of 322, 92.6% ; survived with no recurrence. The histologic subtypes and stages with respect to relapses of preoperatively treated patients are shown in Table 5. No recurrences occurred in the stromal predominant, epithelial predominant and completely necrotic WTeither after immediate surgery or preoperative therapy. The four children who relapsed in the group of immediately operated children died. Two of them died in the progression of the first relapse one with initial stage I tumor of mixed subtype and another with a blastemal predominant tumor of stage III ; , the third following his third relapse initial stage III ; , and another one with initial stage I tumor of mixed histology died in CR after his first relapse due to severe late side effect of the recurrence treatment. The four years recurrence-free survival of the patients who received preoperative chemotherapy was 95.5% 231 of 258 ; Figure 1 ; . Of the 27 patients who relapsed, 16 survived and have remained in CR for at least 57 months maximum 116 months, median 78 months ; since the date of their last event. The death of 10 children was tumor related and 1 further patient died in second CR due to the late side effect of the recurrence treatment. Three of the nine children who relapsed with blastemal.